logo
How to recognize - and overcome

How to recognize - and overcome

Yahoo18-07-2025
You're inferior. Incompetent. Unattractive. Everyone else is better than you are. If there are moments in your life when this is how you feel, it wouldn't be unusual.
For some people, however, self-doubt colours all of their thinking and actions. They believe they're "good for nothing," "worthless" or "unloved." This can be an indication of an inferiority complex.
"'Inferiority complex' isn't a medical term, but rather an everyday one," says Dr Gregor Müller, an instructor at the Institute of Psychological Psychotherapy (IPP) in Bochum, Germany.
As he explains it, an inferiority complex is "a fundamental lack of self-assurance." You have no confidence in yourself, constantly see yourself as a failure and think you never do anything right.
Psychological psychotherapist Eva Maria Klein prefers the term "self-esteem issues" to "inferiority complex." For people who have them, there's a discrepancy between their "ideal self and reality," she says. It arises when they place excessively high demands on themselves, often because of high performance expectations from their parents during childhood.
If reality is at odds with what they come to expect of themselves, they suffer.
Part of the problem, she says, is that people who expect and demand a lot of themselves continually compare themselves with others. While such comparisons aren't unusual, "drawing them constantly, and then feeling inferior, can weigh heavily on them."
Feeling you don't measure up is often accompanied by further negative feelings. "Low self-esteem can also manifest itself in a fear of facing certain situations" and sometimes in a feeling of shame as well, which can make matters worse, Klein says. Depression can result.
To determine whether you have an inferiority complex, simply consider your self-image. What knowledge and skills do you have? What are your strengths, your physical attributes? If you don't see much that's positive, but weaknesses and deficits instead, you might have a problem with your self-perception.
"The more negatively you see yourself, and the stronger you believe that others see you negatively too, the more likely it is that you have an inferiority complex," Müller says.
Feelings of inferiority and the negative thoughts underlying them can often be overcome. "In milder cases, even positive encouragement from friends or some positive feedback at work can be productive," says Müller. Apart from this, you can - and should - take steps yourself to pull up your low self-esteem.
"Although the process may take a while, it can be successful," Klein says. There are several ways to do this, beginning with self-acceptance.
"A first step can be accepting yourself as you are," leaving aside whether your self-perception is positive or negative, Müller says.
In the second step, examine what it is you don't like about yourself, "for instance that you think you're unkempt or too fat." Then you make a plan to address the problems, such as washing your hair more often and always wearing clean clothes, or losing five to 10 kilograms in a certain amount of time.
"Simply raising your awareness about a problem and planning to solve it can begin to boost your self-esteem," Müller says, since you've abandoned your passivity and taken action.
"It can help to take your strengths and successes into account," Klein says. If you give it some thought, you'll surely come up with things about yourself that others find positive too. You can make a note of them, regularly add to the list, and - in phases of self-doubt - go over it to pick up your self-esteem.
Know your own worth. Inferior? Worthless? People are never that, which is something you need to realize. Everyone has strengths and weaknesses.
You can compare yourself with others, of course, and conclude there are certain things you don't do as well. "But that doesn't mean you're of less worth," Müller says. And perhaps you can do things that others can't.
In some cases it can be difficult to overcome self-esteem issues on your own, particularly if they're linked with other symptoms and adversely affect your life. "Psychotherapy can then be effective," Klein says.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth

Yahoo

timean hour ago

  • Yahoo

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. Driven by exceptional growth in Specialty Medicines and Vaccines, GSK's second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding analyst estimates of $10.33 billion. Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $ company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&D) areas, particularly within Oncology and Vaccines. Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan. Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine sales increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). Shingrix sales reached 853 million pounds, up 3% (+6% cc). In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk. Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK's Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. View more earnings on GSK Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds. GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031. Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program. Key trials expected to begin in the second half of 2025 include GSK'227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK'981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months. Tariff Outlook and Guidance Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration's initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of pharmaceutical product imports on national security. The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK's CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly. GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the top of the 3%–5% range. Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage. Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable. Price Action: At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? GSK (GSK): Free Stock Analysis Report This article GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BMA hits back at claims it refused to allow doctors to work in critical areas during strike
BMA hits back at claims it refused to allow doctors to work in critical areas during strike

Yahoo

timean hour ago

  • Yahoo

BMA hits back at claims it refused to allow doctors to work in critical areas during strike

The British Medical Association has hit back at claims the organisation refused to allow doctors to keep working in critical areas during five days of strike action. Resident doctors – previously known as junior doctors – began a five day strike across England on Friday as part of an escalating row between NHS bosses and the BMA over pay. The strike ended at 7am this morning (Wednesday). During a strike, NHS trusts can apply for measures, often called "derogations", which would allow doctors to return to work providing critical services when it is feared patient safety is at risk. In an update to staff on Tuesday morning, Sir James Mackey, chief executive of the NHS, said 18 requests for patient safety mitigations (derogations) had been turned down. Sir Jim claimed that in nine of the 18 cases, the BMA said it would allow doctors to return to work, but only if they were paid "extortionate" rates. "Unfortunately, despite all requests being made and verified by senior medics, 18 have been rejected by the BMA, with half of those rejections saying the BMA would support only if extortionate pay rates were offered to striking doctors," Sir James said. But a spokesperson for the BMA told Sky News the claims by Sir James were "untrue and unfounded". "When a derogation is agreed between the BMA and NHS England and which requires a resident doctor to return to work, they do not receive any kind of enhanced payment because those resident doctors are going back to their ward or department to do their usual work," they said. "Sir James is clearly quite confused about the derogation process if he is suggesting anything different." 'Wholly wrong and untrue' The BMA said before any derogation is granted, a trust is expected to demonstrate it has "done everything possible to incentivise non-striking doctors to cover the vacant shifts". Read more: "This can include paying enhanced rates of pay and this is a usual practice when asking doctors to take on extra-contractual work, over and above their normal hours and is not exclusive to covering gaps that trusts have failed to adequately plan for during industrial action." They said the claim that the BMA requires increased payments to striking doctors is "wholly wrong and Sir James Mackey should withdraw these comments and apologise for the misleading impression they are creating". Fewer patients were affected by the five-day walkout compared to previous strikes, NHS officials said this morning, with fewer doctors taking to picket lines. The number of appointments, procedures and operations that were postponed are expected to be published later this week. But as this week's strike comes to an end, the union is not ruling out further strikes. Health Secretary Wes Streeting has said future talks could lead to improvements in the working lives of resident doctors but he has repeatedly said there is no more money for pay. But BMA leaders have insisted there must be some discussion around pay. Last July, resident doctors were awarded a raise of 22% over two years, the highest public sector award in recent years. But the BMA has argued that pay has declined significantly since 2008, and are calling for a rise of 29.2% to reverse "pay erosion".

Watch and learn, Samsung: This Galaxy Ring competitor now predicts your chances of falling sick
Watch and learn, Samsung: This Galaxy Ring competitor now predicts your chances of falling sick

Android Authority

timean hour ago

  • Android Authority

Watch and learn, Samsung: This Galaxy Ring competitor now predicts your chances of falling sick

Kaitlyn Cimino / Android Authority TL;DR Circular's smart ring is getting a new Immunity Index that measures your defense against diseases. It accounts for your vitals and gives you a rating on a scale of 0–8. The feature is rolling out to the companion app for the first-gen Circular Ring and will be available for the Ring 2, which is expected to be available soon. Even though the smart ring market is still niche, the entry of big players like Samsung with its Galaxy Ring has set it into motion. Besides already established brands like Oura and (relatively) new entrants like Samsung, a host of smaller brands are looking to benefit from this momentum. Circular, one of these brands, is making noise with unusual (for a smart ring) features such as blood pressure and non-invasive sugar level monitoring right from your finger. While we await its newer generation, Circular's existing model is gaining new insights that predict before you fall sick. The first-generation Circular Ring now takes into account vital health metrics, including HRV or Heart Rate Variability, resting heart rate, irregular breathing patterns during sleep, and variations in skin temperature. This data is consolidated into an Immunity Index, which, Circular says, is designed to indicate a user's 'readiness to fight off diseases.' Based on continuous reading of these metrics, the Immunity Index gives a rating out of eight to quantify users' immunity. It will also warn users of their chances of falling sick, similar to what the Apple Watch does through its Vitals app. My colleague Rita El Khoury also discovered a similar feature worked well on her Oura Ring, which notified her before she fell sick. However, both Galaxy Watch and Pixel Watch currently lack features to detect signs of illness. If you're wondering why Circular chose a rating out of eight instead of ten, it is because it has five tiers based on definite ratings, rather than a more descriptive scale. Continuous details these ratings as follows: 8/8: All Clear, where all your metrics lie in the safe zone 6/8: Slightly vulnerable, indicating one of the metrics may be off 4/8: Vulnerable, where multiple factors could indicate stress or lack of rest 2/8: Advanced risk, for multiple factors off the charts 0/8: Major risk, which indicates the requirement of medical attention The brand is also updating its app to allow tracking of potential symptoms. These features will roll out to all users of the Circular Ring and are promised to be available on the Ring 2, which was announced earlier this year and is up for pre-ordering via Kickstarter. Notably, Continuous has amassed pre-orders worth almost $4 million, which is 400 times the initial target. The campaign page says the sizing kits have already started to be shipped to backers, and delivery of the rings is expected to begin very soon. Follow

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store